Nguyen, T. T. T., Torrini, C., Shang, E., Shu, C., Mun, J.-Y., Gao, Q., Humala, N., Akman, H. O., Zhang, G., Westhoff, M.-A., Karpel-Massler, G., Bruce, J. N., Canoll, P., & Siegelin, M. D. (2024). OGDH and Bcl-xL loss causes synthetic lethality in glioblastoma. JCI Insight. https://doi.org/10.1172/jci.insight.172565

Goldberg, D. J., Hu, C., Lubert, A. M., Rathod, R. H., Penny, D. J., Petit, C. J., Schumacher, K. R., Ginde, S., Williams, R. V., Yoon, J. K., Kim, G. B., Nowlen, T. T., DiMaria, M. V., Frischhertz, B. P., Wagner, J. B., McHugh, K. E., McCrindle, B. W., Cartoski, M. J., … Detterich, J. A. (2023). The Fontan Udenafil Exercise Longitudinal Trial: Subgroup Analysis. Pediatric Cardiology, 44(8), 1691–1701. https://doi.org/10.1007/s00246-023-03204-y

Elez, E., Kopetz, S., Tabernero, J., Bekaii-Saab, T., Taieb, J., Yoshino, T., Manji, G., Fernandez, K., Abbattista, A., Zhang, X., & Morris, V. K. (2024). SEAMARK: phase II study of first-line encorafenib and cetuximab plus pembrolizumab for MSI-H/dMMR BRAF V600E-mutant mCRC. Future Oncology, 20(11), 653–663. https://doi.org/10.2217/fon-2022-1249

Di Maria, M. V., Goldberg, D. J., Zak, V., Hu, C., Lubert, A. M., Dragulescu, A., Mackie, A. S., McCrary, A., Weingarten, A., Parthiban, A., Goot, B., Goldstein, B. H., Taylor, C., Lindblade, C., Petit, C. J., Spurney, C., Harrild, D. M., Urbina, E. M., … Schuchardt, E. (2022). Impact of Udenafil on Echocardiographic Indices of Single Ventricle Size and Function in FUEL Study Participants. Circulation: Cardiovascular Imaging, 15(11). https://doi.org/10.1161/circimaging.121.013676